Oncoceutics is developing a novel class of safe and effective cancer therapies called imipridones. Imipridones have a unique three-ring core structure and have been shown to selectively target G protein-coupled receptors (GPCRs). GPCRs are the largest class of surface membrane receptors in humans and a common target of approved drugs that are underexploited in oncology. GPCRs control an array of critical pro-survival and stress signaling pathways that are often dysregulated in human cancer to favor cancer cell survival and propagation.
Expanding Oncoceutics’ development program means generating additional analogs that are selectively targeting GPCRs that offer opportunities in oncology, as well as in other diseases.
The ability of imipridones to target GPCRs with a high degree of selectivity represents a novel opportunity in oncology that can generate remarkably safe and effective therapeutics. The chemistry behind this core structure permits the generation of a large imipridone family of compounds with vast therapeutic potential. Research shows that minor chemical changes cause dramatic shifts in: